Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Liquid Imiquimod Formulation May Induce Immune Response in Bladder Cancer

May 11th 2016

TMX-101 (Vesimune), a liquid formulation of the toll-like receptor 7 agonist imiquimod, appeared safe and demonstrated preliminary clinical activity, including the potential to induce an immune response, in patients with non-muscle invasive bladder cancer.

Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCC

May 11th 2016

Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to antiâ€“PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.

Dr. Infante on AM0010 in Patients With RCC

May 11th 2016

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Dr. Xifeng Wu on Prognostic Factor of Obesity-Related Genes in RCC

May 4th 2016

Xifeng Wu, MD, PhD, chair, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, director, Center for Translational and Public Health Genomics, professor, The University of Texas MD Anderson Cancer Center, discusses the prognostic factor of obesity-related genes in patients with renal cell carcinoma (RCC).

Expert Shares Insight on Promising Entinostat/IL-2 Results in RCC

May 3rd 2016

Robert Pili, MD, discusses the results and significance of an early-phase trial looking at the combination of entinostat and interleuken-2 and how it could shake up the treatment paradigm for renal cell carcinoma.

Dr. Choueiri on FDA Approval of Cabozantinib for RCC

April 26th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of cabozantinib as a second-line treatment of patients with renal cell carcinoma (RCC).

FDA Approves Cabozantinib for Renal Cell Carcinoma

April 25th 2016

The FDA has approved cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy.

Expert Hopes Immunotherapy Combos Will Deliver Durable Remissions in RCC

April 21st 2016

Robert Figlin, MD, discusses some emerging agents and ongoing trials that could transform the treatment landscape of renal cell carcinoma.

Push for Biomarker Development Continues in RCC and Bladder Cancer

April 21st 2016

Sumanta Kumar Pal, MD, discusses the state of biomarker development in the field of genitourinary malignancies.

Entinostat/IL-2 Combination Active in Previously Untreated Renal Cell Carcinoma

April 20th 2016

More than one-third of patients with previously untreated renal cell carcinoma responded to the combination of high-dose interleukin-2 and an investigational histone deacetylase inhibitor entinostat.

Novel Therapies Shaking Up the Renal Cell Carcinoma Landscape

April 13th 2016

Although therapeutic options for renal cell carcinoma have expanded dramatically during the past decade, oncologists are faced with considerable complexity in selecting the right course of treatment for the individual patient.

Dr. Choueiri on Using Immunotherapy to Treat RCC

April 11th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.

Partner's Buy-In Key to Minneapolis Urology Group's Success

April 10th 2016

At Metro Urology of Minneapolis, urologists are at the forefront of introducing new techniques and technology, especially with respect to advanced prostate cancer care.

Nivolumab Approved in Europe for Renal Cell Carcinoma

April 7th 2016

The European Commission has approved nivolumab (Opdivo) for use in previously treated patients with advanced renal cell carcinoma.

Checkpoint Inhibition New Mainstay in Metastatic RCC

April 6th 2016

Immunotherapy should be considered along with VEGF and mTOR TKIs as a highly effective treatment modality for patients with metastatic renal cell carcinoma.

Expert Discusses Evolving Role of Surgery in Kidney Cancer

April 2nd 2016

Alexander Kutikov, MD, discusses the evolving role of surgery in kidney cancer.

Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways

March 29th 2016

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.

Dr. Petrylak on Immunotherapy in Bladder Cancer

March 28th 2016

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.

Immunotherapy a Mainstay in Kidney Cancer, Novel Approaches on Horizon

March 22nd 2016

Mario Sznol, MD, discusses the current state of immunotherapy in renal cell carcinoma, emerging agents and combinations in the field, and the challenges that arise with finding biomarkers.

Dr. Krajewski on Responses With PD-1 Agents in RCC

March 17th 2016

Katherine Krajewski, MD, associate director, physician, Cancer Imaging Program Fellowship, Dana-Farber Cancer Institute, assistant professor of Radiology, Harvard Medical School, discusses the range of responses seen in patients with renal cell carcinoma (RCC) who have received PD-1 agents as treatment.